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Abstract 
A highly sensitive and rapid stability indicating Ultra Performance Liquid Chromatographic 
(UPLC) method was developed for the quantification and identification of isotretinoin in 
bulk. Chromatographic separation was developed using a gradient elution in a reversed-phase 
system at flow rate of 0.5 ml/min with 12 minutes run time. The mobile phase was a gradient 
mixture of mobile phase A (contained a 30:70:0.5 mixture solution of methanol / Purified 
water / Glacial Acetic Acid) and mobile phase B (contained a 70:25:4.5:0.5 mixture solution 
of methanol /Acetonitrile/Purified water / Glacial Acetic Acid). Eluents were monitored at 
355 nm. The analytical method was validated for accuracy, precision, robustness, linearity 
and forced degradation in accordance with ICH topic Q2 (R1) Validation of Analytical 
Procedures: Text and Methodology. The method was linear over a concentration range of (1-
7 µg/mL) with correlation coefficient of (r
2
 > 0.9999). The accuracy was confirmed by
calculating the % recovery which was found to be 100.1 – 101.6%. The RSD values obtained 
for repeatability and intermediate precision experiments were less than 2%. The limit of 
detection (LOD) was (0.12 µg/mL) while the limit of quantification (LOQ) was (0.38µg/mL). 
The drug samples were exposed to different stressed conditions and the results showed that 
all degradation products were satisfactorily separated from each other and from the peak of 
the drug using the developed method. The proposed method can be used for the quantitative 
determination of isotretinoin with confidence.  
Keywords: Isotretinoin; Method development, UPLC, Forced degradation studies, ICH 
guidelines. 
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1. Introduction
Isotretinoin is an active pharmaceutical ingredient (API) used as an oral (systemic) treatment 
of severe form of acne which is also known to be one of the most useful vitamin A derivatives 
that affects all the major factors involved in the pathogenesis of acne [1]. It is a cis-vitamin A 
acid (synthestic vitamin A acid derivative) and a stereoisomer of Tretinoin and isomer of 
Alitreitnoin. It is chemically described as (2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimehtyl-1-
cyclohexenyl)nona-2,4,6,8-tetraenoic acid (also known as 13-cis-retinoic acid) [2]. 
Isotretinoin has a small molecular weight (300.44) and is pratically insluble in water [3]. The 
structural formula of isotretinoin and its isomoers, tretinoin and alitretinoin are as shown in 
schemes 1.a-c [4]: 
Scheme 1.a. Chemical structure of Isotretinoin (13-cis-retinoic acid) (4) 
Scheme 1.b. Chemical structure of Tretinoin (all-trans-retinoic acid) (4) 
Scheme 1.c. Chemical structure of Alitretinoin (9-cis-retinoinc acid) (4) 
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Several analytical methods utilizing High Performance Liquid Chromatography (HPLC) have 
been developed for quantitation of isotretinoin in pharmaceutical dosage forms including 
both capsule and topical gel [2]. An isocratic reversed phase HPLC was developed by 
Mahajan et al. (2016) [2]. Normal phase HPLC method was employed in the United States 
Pharmacopoeia (2007) and another method was reported to determine both isotretinoin and 
tretinoin simultaneously in the dermatological formulations by Tashtoush et al. (2007)[, a 
reversed phase method equipped with fluorescence detector has also been described by Gatti 
et al. (2000)[6].  However, most of these methods were associated with large consumption of 
solvents, long run time, the use of undesirable reagents such as Tetrahydrofuran (TFA), poor 
sensitivity and poor resolution from retinoic isomers [2, 5]. 
In contrast to HPLC, Ultra-performance liquid chromatography (UPLC) is functionally 
advanced in its rapidness, sensitivity and resolution [7]. It can withstand much higher back 
pressure with smaller packed column, lower injection volume and shorter run time [7, 8]. 
UPLC Technology is able to provide numerous benefits to routine testing of commercialised 
drug products, with increased sample throughput and decreased solvent consumption [9, 10]. 
This indicates that an analytical testing method using UPLC may offer significant cost 
effectiveness by analysing more samples per system in lesser time. The overall operating 
expense in both development and quality control thus can be reduced with increased 
productivity. All these advantages over conventional HPLC has allowed UPLC to gain its 
place and popularity in the industry for both routine and research purpose nowadays [11]. It is 
thus highly desirable to develop and validate an UPLC method for isotretinoin with 
satisfactory resolution, sensitivity and relatively short analysis run time in line with routine 
analysis for quality control purposes. To the best of our knowledge, there is no published 
work involves development of an analytical method for quantification of isotretinoin using 
UPLC. Therefore, aim of the present work was to develop and validate a stability indicating 
method for isotretinoin using UPLC method. 
2. Materials and Analytical Testing Method
2.1 Chemicals and reagents 
Isotretinoin Standard (USP) and Tretinoin (USP) were purchased from United States 
Pharmacopeial Convention, USA. Alitretinoin was purchased form Olon S.P.A, Italy. 
Tetrahydrofuran, Methanol and Acetonitrile were procured from EMD Millipore 
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Corporation, Germany. Glacial Acetic Acid (GAA) was purchased from VWR International 
S.A.S, France. All the organic solvents were gradient grade. Purified water was obtained by 
MllieQ water purifier system, Auckland, New Zealand, Isotretinoin Active Pharmaceutical 
Ingredient (API), BASF, New Zealand.  
2.2 Laboratory Preventive Measure 
Isotretinoin is sensitive to light, heat and air, hence exposure of isotretinoin to strong light is 
to be avoided [2]. Therefore, all experiments were performed under the recommended 
conditions of protection from actinic light, i.e. performing the test in a room fitted with the 
appropriate light filters. 
2.3 Chromatographic System and Condition 
The UPLC analysis was performed on UPLC System gradient with UV Detector (Dionex 
UltiMate or equivalent) controlled through Chromeleom Software. Analytical Column used 
for this method was C18, SB, 1.8 µm, 2.1mm x 150 mm (Waters Acquity HSS C18 SB, or 
equivalent). The mobile phase was a gradient mixture of mobile phase A (contained a 
30:70:0.5 mixture solution of methanol / Purified water / Glacial Acetic Acid) and mobile 
phase B (contained a 70:25:4.5:0.5 mixture solution of methanol /Acetonitrile/Purified water 
/ Glacial Acetic Acid). Both mobile phase A and B were filtered and degassed through 0.22 
µm membrane filter. The final gradient program [(min)/%B] was 0/62, 7/62, 8.5/100, 
9.5/100, 9.5/62 and 12/62 (Table 1). The flow rate was set at 0.5 ml/min. The column 
temperature was 55
o
C. The sample compartment was 4
o
C. The injection volume of sample
was 2 µl. The eluent was analyzed by UV Detector at wavelength of 355nm. An ultrasonic 
bath from Bandelin Sonorex (Germany) was used for standard and sample sonication.  
2.4 Preparation of solutions 
2.4.1 Standard solution preparation 
Isotretinoin stock standard solution (250µg/mL) was prepared by weighing appropriate 
amount isotretinoin USP standard into 100 mL volumetric flask. 20 mL THF 
(Tetrahydrofuran) was added to completely dissolve the standard with at least 5 minutes of 
sonication and made up to volume with methanol. 5 µg/mL working solution was prepared by 
further dilution from the stock solution and made up to volume with methanol.  
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2.4.2 Sample solution preparation 
Isotretinoin sample stock solution was prepared by weighing appropriate amount isotretinoin 
into volumetric flask, dissolve with 20 mL THF with at least 5 minutes of sonication and 
made up to volume with methanol. 5 µg/mL working solution was prepared by further 
dilution from the stock solution and made up to volume with methanol.  
2.5 Method validation 
The developed UPLC method was  validated in accordance to ICH topic Q2 (R1) validation 
of Analytical Procedures: Text and Methodology [11] for the following. 
2.5.1 Accuracy 
Accuracy of the developed method was determined by calculating the percentage recovery of 
the analyzed spiked samples [11]. Known amount of isotretinoin were spiked in triplicates at 
different concentration levels of 60%, 100% and 140%.  
2.5.2 Precision 
Six individual samples of 100% were prepared to assess the closeness of agreement between 
series of measurement [12]. The %RSD value was calculated.  
2.5.3 Intermediate precision 
Reproducibility of testing method was examined as follows: Six samples at 100% level were 
prepared and analyzed on different days, instrument, column, mobile phase [12]. The % RSD 
values was calculated for all the replicates (combining from two analysis) 
2.5.4 Linearity and range 
Linearity was required to demonstrate that the detector response is directly proportional to the 
analyte concentration over a specific range [12]. A minimum of five solutions at the 
concentration from 1 to 7 µg/mL were prepared for linearity study. Duplicate injections of 
each solution were performed and 10 injections were performed on 100% working solution 
for instrument repeatability. The calibration curve was constructed and linear regression 
equation was obtained. The %CV (RSD) between the peak area and the actual concentration 
should be not less than 0.999. 
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2.5.5 Robustness 
Robustness was assessed by altering chromatographic condition [2,12]. Chromatographic 
system variation was evaluated by using flow rates of + 0.05 mL/min and column 
temperature of + 2
o
C from the nominal conditions of 0.5 mL/min and 55
o
C. Combinations of
variation are presented in Table 2, which shows four different variables. The recovery was 
studied and compared with nominal condition. The suitability of variation was thus 
determined.  
2.5.6 LOD and LOQ 
Detection and Quantitation limits are the lowest detectable and quantifiable concentration 
that a method can achieve. As per ICH guideline, the LOD and LOQ were determined based 
on the standard deviation of the response and the slope using the formulae provided  below. 
The detection limit (DL) is expressed as [12]: 
LOD=3.3*σ/S 
where σ = the standard deviation of the residue 
S = the slope of the calibration curve 
The quantitation limit (QL) is expressed as: 
LOQ=10*σ/S 
where σ = the standard deviation of the residue 
S = the slope of the calibration curve 
2.5.7 Forced degradation studies 
Forced degradation studies were conducted to ensure that the analytical method was stability 
indicating and to demonstrate the ability of the method to separate isotretinoin from its 
degradation end products. Isotretinoin active ingredients were weighed and stressed with 
stressors that are recommended in the regulatory guideline [12] and analysed for isotretinoin 
contents. Acid degradation was carried out by incubating isotretinoin with 2M Hydrochloric 
acid (HCl) for 1 day. Alkaline degradation was carried out by stressing isotretinoin for 7 days 
with 1M Sodium Hydroxide (NaOH). The oxidative study was carried out by stressing 
isotretinoin with 20 mL of 30% H2O2 for 8 hours. Thermal degradation was done by exposing 
sample at 95
o
C for 3 days. Hydrolysis was done by adding 20 mL of purified water into
sample for 3 days. Light degradation studies on isotretinoin were carried out by exposing the 
sample to visible light which was not less than 1200000 lx.h and UVA radiation of 220 
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W.h/m
2
. Samples were withdrawn at specified time points. The stressed samples were
neutralized (acid and base only), prepared to assay concentration and analyzed according to 
the chromatographic conditions with UV detection at 355nm.The stressed conditions are 
listed in Table 4. 
3. Results and Discussion
3.1 Method development and optimization 
Originally, the UPLC method we developed for the analysis of isotretinoin was based on an 
isocratic HPLC method as detailed by [2]. The method developed   using a RP-C18 column 
(250 x 4.6mm, 5 µm particle size) with 10 minutes run time at flow rate of 0.8ml/min. 
Wavelength set at 355 nm with injection volume of 20 µl. The Mobile phase was constituted 
of 50:45:5 (Acetonitrile/Methanol/water), pH adjusted to 4.5 using (Glacial acetic acid) 
GAA. A wavelength of 355 nm was used as it has identified as a suitable wavelength for 
quantifying isotretinoin. A trial injection was made for isotretinoin standard sample spiked 
with alitretinoin and tretinoin. The results showed that the reference method was able to 
separate isotretinoin from alitretinoin and tretinoin (Figure 1.a). However, (Figure 1.b) shows 
that both tretinoin and alitretinoin may have co-eluted as one single peak.  
When an UV degraded isotretinoin standard solution as injected, a shoulder peak that was 
not separated from isotretinoin peak was also observed which suggested that there was co-
elution underneath isotretinoin peak (Figure 1.c). These findings suggested that the current 
column or mobile phase composition was inefficient to separate the impurities or isomers that 
were closely related to isotretinoin. Adjustments in flow rate, run time or temperature under 
an isocratic elution program were thought to be uneconomical, as a prolonged run time would 
be required to achieve satisfactory resolution.   
Due to the observed deficiencies, we s decided to modify our original  UPLC method in order 
to  capture any possible degradants as well as to ensure  that they were well separated from 
isotretinoin peak with reasonably short run time. Several modifications based on the current 
isocratic method were considered for the development of UPLC method. The UV degraded 
standard solution (isotretinoin) and spiked tretinoin and alitretinoin solutions were used to 
modify the method and to optimize the chromatographic conditions. To achieve satisfactory 
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resolution and good chromatography, the RP-C18 column (250 x 4.6mm, 5 µm particle size), 
used in our original method which was a long column packed with larger particles and 
showed lack of resolution, was replaced with a shorter column packed with smaller particles 
eg. C18, SB, 1.8 µm, 2.1mm x 150 mm.  The injection volume was lowered to less than 2 µL 
due to smaller column volume.  
The composition of mobile phase with 0.5% glacial acetic acid (GAA), methanol and 
acetonitrile were re-adjusted and optimized through multiple trials by achieving the 
separation of isotretinoin, light degraded impurities, tretinioin and alitretinoin using the UV 
degraded standard solution (isotretinoin). Introduction of gradient elution program with high 
organic portion near the end of each injection may have served as a strong wash phase to 
elute out the impurities, isomers, unwanted waste or residue to avoid blockage of column or 
carry over. The details of the gradient elution programme and the modified mobile phase can 
be seen in (section 2.3 and table 1). Moreover, acetonitrile was used as a solvent of 
isotretinoin to prepare the samples in the original method. Since the proportion of methanol 
in mobile phase was relatively higher than acetonitrile, methanol was proposed to replace 
acetonitrile in the modified method. Standard or bulk active pharmaceutical ingredient (API) 
would therefore be prepared in methanol. Figure 2 shows the UV light degradants (degradant 
2 and degradant 3) were separated from isotretinoin with a resolution of 1.5 and 2.0, while 
the resolution between tretinoin and alitretinoin was 3.3. That was a great improvement in 
terms of resolution from the original isocratic HPLC method with the run time of 12 minutes 
only.   
3.4 Method Validation 
Ovearll, a Gradient reverse-phase UPLC method has been followed to develop an assay for 
determination of isotretioin cocentration in isotreitnoin or related products. Quantitation of 
isotreitnoin was carried out via comparison with an external isotretinoin standard. The 
validation would be in accordance with ICH topic Q2 (R1) validation of Analytical 
Procedures: Text and Methodology (2005).  
3.4.1 Accuracy 
Accuracy was required to demonstrate that the analytical procedure would provide results 
that reflect the true value for the material across the specified range of the analysis. The mean 
percentage recovery at each level should be within 98.0-102.0 with %RSD less than 2.0%. 
The recovery was calculated using linear regression equation (Table 3.a) that was established 
within the range of 60% - 140% (3µg/ml - 7µg/ml). Table 3.b shows the results of accuracy 
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studies.  As the recovery values were in the range of 100.1 – 101.6% and the %RSD of all 
three levels was 0.79, the relative response factors and recovery data reported in Table 3.b 
indicate that the method is accurate. The retention time, theoretical plate and tailing factor 
were also reported to demonstrate that the chromatographic condition of isotretinoin peak 
was successfully obtained.  
3.4.2 Precision, Intermediate Precision, Injection Repeatability 
The repeatability and intermediate precision were determined as described in Section 2.5.2 
and 2.5.3. As Per ICH guidelines (2005), the %RSD value between six individual samples 
should be less than 2.0%. Our results which are listed in Tables 4.a and b reveal that the 
%RSD value for precision study of six 100% solutions was 1.5 %, which was meeting criteria 
of 2.0%. The %RSD value of twelve individual results from two days of study was 1.5% 
which was also less than   2.0% for intermediate precision. This suggested that the method 
was accurate and precise as acceptable recovery and precision has been achieved from 60%-
140%. %RSD value for Instrumental repeatability of ten injections on the 100% sample 
solution was 0.76 indicating the injection repeatability was also precise (Table 4.b). 
3.4.3 Linearity and Range 
A series of solutions containing isotretinoin at concentration of 20% to 140% (1µg/ml - 
7µg/ml) of the nominal concentration were analysed to determine the linearity of the 
proposed method. The peak area versus concentration data were treated by least-squares 
linear regression analysis. The result from Linearity and range assessment suggested that the 
method is linear with R² value equal to 0.9999, the linear regression equation obtained was 
22410x+213.33 (Table 5).  
3.4.4 Limit of detection (LOD) and limit of quantitation (LOQ) 
The analytical method showed good linearity within the specified range. The LOD and LOQ 
were calculated based on standard deviation of residue (843.2795) and slope (22410) as per 
formula provided in ICH guideline (11) and they were 0.12µg/ml and 0.38 µg/mL 
respectively. 
3.4.5 Robustness - Chromatographic Parameter Variations 
Robustness was assessed by altering the chromatographic conditions including flow rate and 
column temperature listed in Table 6. The number of theoretical plates and the tailing factors 
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were within the acceptance criteria of greater than 20000 and 0.8-1.5 respectively. The 
%RSD value of results between nominal and combination of changes was only 0.54 
demonstrating that the chromatographic condition was robust and reliable results can be 
obtained within the prescribed degree.  
3.4.6 Forced degradation studies 
Stress study should be carried out to establish the inherent stability characteristics of drug as 
according to drug stability guideline Q1A (R2) issued by ICH [13]. Therefore, it is essential 
to have a stability indicative testing method for pharmaceutical development. The method is 
used to detect how the stability of the drug substances or products that can be changed with 
time under specified stress conditions. It should be able to measure the changes in active 
ingredient level accurately without interference from degradants, impurities or formulation 
matrix [14]. It is also useful to predict the degradation of drug compound at early stage of 
development when the availability of information is limited. Several methods using HPLC 
for isotretinoin quantitation were recently developed and validated by Mahajan et al., 2016 
Guimaraes et al., 2010; and Dalvi et al., 2016 [ 2, 15, 16], however, only accuracy, linearity, 
precision and robustness were covered by the validation [14, 15] . Forced degradation was 
not being conducted for all the HPLC methods. Tashtoush et al (2007) [5] has conducted 
photostability study on tretinoin and isotretinoin, however, the authors claimed that the 
method was not qualified as a stability indicating method as the separation parameters 
between retinoic acids and its degradant required more attention in order to achieve better 
resolution. Hence, the proper degradation profile of isotretinoin remains unknown. In our 
study, the degradation experiments were therefore carried out on isotretinoin using the newly 
developed UPLC method to determine the stability-indicating property of the method.  
Recovery of isotretinoin in each stressed sample was calculated relative to an unstressed 
sample using data acquired at 355 nm. As the concentration of working solution was only 
5µg/ml, degradation under mild stress conditions might be insufficient to produce desired 
amount of degradants to be detected on the chromatograms. Our aim was therefore to achieve 
degradation with relatively harsh conditions to generate desired amount of degradation 
products that can be used to assess the analytical methods performance suggested by Singh et 
al (2013) [17]. The results of the percentage recovery of the stressed samples and the number 
of degradants produced are summarized in Table 7. The percentage recovery of the light 
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stressed sample was 90.9%, 87.9% for heat, 81.0% for oxidation, 93.7% for hydrolysis, 
73.7% for acid stressed sample, and 97.3% for base stressed samples. Among all of the 
stressed samples studied, only based stressed samples showed a degradation of less than 5% 
even after 7 days incubation with 1M NaOH. This suggests that isotretinoin is relatively 
stable in basic conditions. On the other hand, extensive degradation was observed for acid 
stressed sample with production of seven degradants. Other stressed samples including heat, 
hydrolysis, light and oxidation have all produced various degrees of unknown degradants at 
355nm. Calculation of mass balance (using % area) was attempted but was not precise as 
100% recovery cannot be obtained for some of the stress conditions e.g. acid. This might be 
due to the degradants not having the same UV spectra of isotretinoin or the absorptivity 
coefficient may have different values according to Cione et al. (2011) [18].  
The ICH guideline (2003) has also commented that mass balance is not achievable in all 
circumstances with due consideration of the margin of analytical precision. The focus of the 
forced degradation may instead be on assuring the specificity of the assay and completeness 
of the investigation of the degradation route (Riley and Rosanske 1996) [19]. It was therefore 
important to demonstrate the ability of the method to resolve the degradants from its principle 
peak which was confirmed by analysing the resolutions of the nearest degradants. Figures 
3.a-f of light, heat water, and acid stressed samples show unknown degradant peaks eluted
before isotretinoin peak. The resolution between isotretinoin peak and the peaks of nearest 
impurities eluted before isotretinoin were 1.6, 1.7, 1.6 and 10.5 respectively. Apart from base 
stress sample which showed no degradant before and after isotretinoin peak at wavelength 
355nm, a resolution of more than 1.5 was achieved for all nearest degradants that eluted after 
isotretinoin for all the stressed samples investigated. The method was therefore proven to be 
stability-indicative as it was not only able to reflect on the recover  of isotretinoin under 
various stressed conditions, but resolution between the degradants and isotretinoin peak was 
also achievable with satisfaction at 355nm.  
According to ICH guidelines, the information generated from the forced degradation studies 
is important to determine the intrinsic stability of the drug molecule and to select proper 
formulation, packaging and appropriate storage conditions to maintain the drug in stable form 
for long period of time. 
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3.4.7 Specificity 
 USP defines specificity as the ability to assess unequivocally the analyte in the presence of 
components that may be expected to be present, such as impurities, degradation products, and 
matrix components. Our method was considered a specific as there was no interference from 
other spiked components including tretinoin and alitretinoin with the isotretinoin peak at 
wavelength 355 nm (Figure 4). Table 8 shows that the resolution between isotretinoin and 
alitretinoin was 6.981. Even alitretinoin and tretinoin were also well separated from each 
other with resolution of 3.461, which allowed identification of individual isomers that might 
be appearing during processing or storing. This improvement in separation between retinoic 
related substances eg tretinoin, isotretinoin and alitretinoin has addressed the poor resolution 
issue that was previously raised by Tashtoush et al (2007) [5]. Moreover, the principle peak in 
the stressed sample has demonstrated to be resolved from other forced degradants. 
4. Conclusion
A simple, rapid and economical UPLC method has been developed for qualification and 
quantification of isotretinoin in bulk drug. The developed method was validated against the 
current ICH guideline and showed the ability of delivering accurate, precise, specific, linear 
and robust results within the validated range. The study has also concluded that isotretinoin is 
most labile to acid, oxidative stress and thermal degradation, and more stable against 
photolysis, alkaline and hydrolysis. Degradants and spiked retinoic acids were present 
without interfering isotretinoin to show the method is stability indicating. The analytical 
method therefore may be used for assay of isotretinoin and identification of isotretinoin and 
its isomers ie. tretinoin and alitretinoin for routine quality assessment and stability study. 
Conflict of interest 
The authors declare that there is no conflict of interest 
Acknowledgement 
Financial, equipment and reagents support from Douglas Pharmaceutical (NZ) Ltd is 
gratefully acknowledged.  
Page 13 of 32
URL: http://mc.manuscriptcentral.com/lpdt
Pharmaceutical Development and Technology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
References 
1. J. Leyden, J. Rosso, and E. Baum. The Use of Isotretinoin in the Treatment of Acne
Vulgaris Clinical Considerations and Future Directions. Supplement to the J of Clin and
Aesth Dermatol. 7 (2014) 4-21.
2. M. Mahajan, R. Singh, S. Jain. Development of a reproducible, sensitive and rapid
reversed phase chromatographic method for the estimation of isotretinoin incorporated in
bulk drugs, pharmaceutical dosage forms and biological matrix. Cur. Pharm. Anal. 12 (2016)
278-85.
3. Technical Information - Isotretinoin. BASF Group. 2008(03_030772e-08):1-4.
4. S. Mukherjee, V. Patravale. Retinoids in the treatment of skin aging: an overview of
clinical efficacy and safety. Clin Interv in Ag.1 (2006) 327-48.
5. B. Tashtoush, E. Jacobson, M. Jacobson. A rapid HPLC method for simultaneous
determination of tretinoin and isotretinoin in dermatological formulations. J. of Pharmac. and
Biomed. Anal. 19 (2007) 859-64.
6. R. Gatti, M. Gioia and V. Cavrini. Analysis and stability study of retinoids in
pharmaceuticals by fluorescence. J Pharm Biomed Anal. 1;23(1) (2000) 147-159.
7. L. Nováková, L. Matysová, P. Solish. Advantages of application of UPLC in
pharmaceutical analysis. Tal. 68 (2006a) 908-18.
8. L. Nováková, L. Matysová, P. Solish. Advantages of ultra performance liquid
chromatography over high-performance liquid chromatography: comparison of different
analytical approaches during analysis of diclofenac gel. J Sep Sci. 29 (2006b) 2433–43.
9. T. Wu, C. Wang, X. Wang, H. Xiao, O. Ma. Comparison of UPLC and HPLC for
analysis of 12 phthalates. Chromatog. 68 (2008) 803-806.
10. A. Stephen, C. Wren, P. Tchelitcheff. Use of ultra-performance liquid chromatography
in pharmaceutical development. J. of Chromatog. A. 1119 (2006) 140-146.
11. B. Pratima, S. Zibran. 2013. Review of Ultra Performance Liquid Chromatogrpahy
and its Application. Int. J. of Res. in Pharm. and Sci. 23 (2013) 19-40.
12. ICH Harmonised Tripartite Guideline Validation of Analytucal Procedures: Text and
Methodology Q2(R1). International conference of harmonisation of technical requirements
for registration of pharmaceuticals for human use. 2005.
13. International Conference on Harmonization. Stability Testing of New Drug
Substances and Product. Q1A(R2). IFPMA, Geneva, Switzerland. 2003.
14. FDA Guidance for Industry, Analytical Procedures and Methods Validation:
Chemistry, Manufacturing, and Controls Documentation, Draft Guidance. Food and Drug
Administration. 2000.
15. C. Guimarães,  F. Mena, B. Mena, I. Ivo Lebrun, J. Quenca-Guillen, A. Auada, L.
Mercuri, P. Ferreira, M. Santoro. Determination of isotretinoin in pharmaceutical
formulaitons by reversed-phase HPLC. J. of Biomed. Sci. and Engineer. 3 (2010) 454-8.
16. S. Dalvi, P. Ingale, S. Hatture. Validated HPLC method for simultaneous estimation of
isotretinoin and erythromycin in bulk drug form. Indo Amer. J. of Pharm. Res. 6 (2016) 5254-
5259.
17. S. Singh, M. Junwal, G. Modha, H. Tiwari, M. Kurmi, N. Parashar N and Sidduri P
Forced degradation studies to assess the stability of drugs and products. Trends Anal Chem
49 (2013) 71-88.
18. A. Cione, E. Tonhi and P. Silva P  Stability Indicating Methods. Quality Control of Herbal
Medicines and Related Areas. Prof. Shoyama Y. InTech: (2011) 25-36.
19. C. Riley and T. Rosanske. Development and validation of analytical methods 1st ed.
Progress in Pharmaceutical and Biomedical Analysis. (1996).
Page 14 of 32
URL: http://mc.manuscriptcentral.com/lpdt
Pharmaceutical Development and Technology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Page 15 of 32
URL: http://mc.manuscriptcentral.com/lpdt
Pharmaceutical Development and Technology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Table 1. Gradient elution program for isotretinoin assay. 
Time (min) Mobil Phase A % Mobile Phase B % 
0 38 62 
7 38 62 
8.5 0 100 
9.5 0 100 
9.5 38 62 
12 38 62 
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Table 2. Chromatographic variation condition 
Method Column 
Temperature(C
o
)
Flow Rate 
(mL/minute) 
1 53 0.45 
2 53 0.55 
3 57 0.45 
4 57 0.55 
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Table 3. Range for Accuracy data calculation. a 
Parameter Values 
Linearity range (3-7µg/mL) 60-140%
Slope 5842.5x
Intercept 471.43
Correlation Coefficient 0.9999
Regression equation y=5842.5x + 471.43
 Accuracy data. b 
Concentration 
(%) 
Theoretical 
(mg) 
Recovered 
(mg) 
Accuracy 
(%) 
Retention Time 
(min) 
Theoretical 
plate 
Tailing Factor 
60 15 15.24 101.6 7.7 20550 1.1 
100 25 25.1 100.4 7.7 20624 1.1 
140 35 35.04 100.1 7.7 20626 1.1 
Mean 100.7 7.7 20600 1.1 
RSD (%) 0.79 0.0 0.2 0.0 
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Table 4. 
 Precision data and intermediate precision. a 
Concentration (%) Precision 1 Precision 2 
101.9 101.5 
100.5 97.6 
100% 98.7 98.9 
98.8 98.0 
98.1 100.8 
98.3 100.4 
Average (%) 99.4 99.5 
%RSD 1.5 1.6 
Intermediate Precision (n=12) 
Average (%) 99.5 
%RSD 1.5 
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Injection Repeatability. b 
Injection 
Number 
 (n) 
Peak Area 
1 114571 
2 113440 
3 114119 
4 113394 
5 112009 
6 112073 
7 113271 
8 112508 
9 113128 
10 114058 
Average (%) 113257 
%RSD 0.76 
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Table 5. Linearity and Limits 
Parameter Values 
Linearity range (1-7µg/mL) 20-140% 
Slope 22410x 
Intercept 213.33 
Correlation Coefficient 0.9999 
Regression equation y=22410x + 213.33 
LOD (µg/mL) 12µg/ml 
LOQ (µg/mL) 0.38 µg/ml 
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Table 6. Robustness data 
Method Column 
Temperature(C
o
)
Flow Rate 
(mL/minute) 
Retention 
Time 
(min) 
Tailing 
Factor 
Theoretical 
plate 
Resolution with nearest 
peak 
Recovery 
(%) 
Before After 
Nominal 55 0.50 7.8 1.2 23303 1.6 2.1 98.1 
1 53 0.45 8.8 1.1 25562 1.6 2.1 98.3 
2 53 0.55 8.3 1.2 24796 1.7 2.1 98.2 
3 57 0.45 8.1 1.2 24221 1.6 2.1 98.2 
4 57 0.55 7.2 1.2 23285 1.5 2.0 99.4 
Mean 98.4 
%RSD 0.54 
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Table 7. Forced degradation data 
Stress Types 
Stress 
conditions 
Assay Recovery 
(%) 
Mass Balance 
(%) 
No. of Degradants/impurities 
at 355 nm 
Resolution between 
nearest degradant 
Known (Tretinoin) Unknown Before After 
Light 
visible light 
not less than 
1200000 lx.h 
followed by 
UVA ration 
at 220 
W.h/m
2
 90.9  98.5 1 1 1.6 12.6 
Heat 
95
o
C for 3
days 
 87.9  97.5 1  2 1.7 12.6 
Oxidation 20 mL of 
30% H2O2 
for 8 hours 
 81.0 
 99.4 1 peak not found -* 12.2 
Hydrolysis 20 mL of 93.7  98.0 1 1 1.6 12.4 
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purified 
water into 
sample for 3 
days 
Acid 2M HCl for 1 
day 
73.7 88.7 1 6 10.5 12.6 
Base 
1M NaOH for 
7 days 97.3 
 97.3 peak not found peak not found -* -* 
-*: No nearest peak was identified. 
Table 8. Specificity study 
Compound Retention 
time 
RSD 
(%) 
Tailing 
Factor 
RSD 
(%) 
Resolution RSD 
(%) 
Isotretinoin 7.56 0.06 1.1 0.0 
6.987 0.01 
Alitretinoin 9.075 0.03 1.0 0.0 
3.461 0.02 
Tretinoin 9.657 0.0 1.1 0.0 
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Figure 1.a. Standard solution spiked with isotretinoin and tretinoin 
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Figure 1.b. An overlay of alitretinoin (7.521min), isotretinoin(6.886 min) and tretinoin (7.582 min) 
solution. The alitretinoin peak elute about the same time as tretinoin. 
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Figure 1.c. UV light degraded standard solution, a shoulder was noticed on the isotretinoin peak 
(isotretinoin at 6.914 min, tretinoin at 7.569min). 
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Figure 2. UV light degraded standard solution. Resolution between of isotretinoin and its light 
degradant 1 was 1.5 and 2.0 for light degradant 2. Resolution between alitretinoin and tretinoin was 
3.3. 
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a. Unstressed isotretinoin solution.
b. Light Stressed solution
c. Heat stressed solution
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d. Peroxide stressed solution
e. Hydrolysis solution
f. Acid stressed solution
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g. Base stressed solution
Figure 3. Chromatograms of isotretinion samples exposed to different stressed conditions 
(a) Unstressed samples (b) light (c) Heat, 95C (d) H2O2 (e) hydrolysis by exposing to
water (f) HCl (g) 1M NaOH. 
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Figure 4. Spiked alitretinoin (3rd peak) and tretinoin (2nd peak) did not interfere with isotretinoin 
(1st peak). Alitretinoin and tretinoin were also well separated from each other. 
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